US oncology-focused biotech firm Ignyta (Nasdaq: RXDX) says it has acquired exclusive worldwide rights relating to pharma major Eli Lilly’s (NYSE: LLY) taladegib oncology development program in exchange for an upfront payment of $2.0 million in cash and the issuance to Lilly of around 1.2 million shares of Ignyta’s common stock.
Taladegib is a potent, orally bioavailable small-molecule hedgehog/smoothened antagonist that has achieved clinical proof-of-concept and a recommended Phase II dose based on results from prior clinical studies. Ignyta also licensed exclusive worldwide rights to the topical formulation of taladegib, which is a late preclinical program being developed for the potential treatment of patients with superficial and nodular basal cell carcinoma.
Concurrent $30 million equity investment in Ignyta by Lilly
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze